Health Canada recalled specified lots of two JAMP prenatal multivitamins after testing found the nitrosamine impurity N-nitroso-folic acid above the acceptable intake limit. The alert concerned an impurity associated with folic acid in affected products; it did not say that the labelled amount of folic acid itself was excessive.
Products and lots covered by the recall
The recall named JAMP Pregnancy Multivitamin, DIN 02535718, supplied as blue tablets containing 1.1 milligrams of folic acid, and JAMP Pregnancy Multivitamin Folic 5, DIN 02537478, supplied as dark-blue tablets containing five milligrams of folic acid. Health Canada’s updated notice listed lots LKE05, LKE07, LKE08 and LKE09 for the first product, and LKE10, LKE11 and LKE14 for the Folic 5 product.
Consumers should compare both the product name and lot number on their packaging with the official recall notice. Similar-looking prenatal vitamins or a different lot are not automatically included. The Drug Identification Number is another useful check because it identifies the authorized product formulation.
What the health concern means
Nitrosamines are impurities that can form during manufacturing or storage. Long-term exposure to some nitrosamines above acceptable levels may increase cancer risk. Health authorities set conservative daily intake limits to reduce lifetime exposure; exceeding such a limit does not mean that a person who took a tablet will develop cancer or face an immediate emergency.
Risk depends on factors including the amount, duration of exposure and an individual’s health circumstances. The recall was classified as Type II, a category generally used when a product may cause temporary adverse health consequences or when the probability of serious harm is considered remote. That classification should not be read as a reason to ignore the notice.
What patients should do
Health Canada advised patients to consult a health-care professional before stopping the affected medication. That is especially important during pregnancy because folic acid is used to reduce the risk of neural-tube defects, and some people are prescribed a higher dose for specific medical reasons. Abruptly abandoning prenatal supplementation without an appropriate replacement can create a different health risk.
A pharmacist or prescribing clinician can confirm whether a package is affected, discuss the duration of use and recommend an alternative product. Consumers should follow the return or disposal directions provided by the pharmacy, retailer or manufacturer rather than giving the tablets to another person.
Why precise recall language matters
The original short headline’s phrase “too much folic acid” can create the wrong impression. The regulatory issue was the level of N-nitroso-folic acid in specified lots, not a general finding that recommended folic-acid supplementation is unsafe. Folic acid continues to be an important part of preconception and prenatal care when used as directed.
People who experience an adverse effect can report it through Health Canada’s vigilance program. Anyone needing urgent medical help should contact local emergency services or a poison-control centre as appropriate. Recall notices may be expanded when new testing is completed, so the current federal notice remains the authoritative place to verify products and lot numbers.
